• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Precision Therapeutics changes name to Helomics, reorganizes management

Precision Therapeutics changes name to Helomics, reorganizes management

November 14, 2014
CenterWatch Staff

Precision Therapeutics has changed its name to Helomics, a Pittsburgh, Pa.-based, privately held comprehensive personalized healthcare company that develops next-generation diagnostics for the oncology field.

Helomics believes each patient is unique, and his/her cancer treatment should be as well. The name reflects the company's new strategic vision, growth strategy and in-depth approach to characterizing patients' live and archived cancer cells. The company is committed to advancing leading-edge and proprietary technology platforms in cellular analysis, genomics, proteomics and bioinformatics combined with a precise and personalized reporting system for tumor profiling and predictive analytics that help physicians to individualize treatment options for their patients.

The company's flagship product, the ChemoFx Chemoresponse Marker (ChemoFx), helps improve patient outcomes by supporting physicians in the selection of effective treatments for women with gynecologic cancer.

Helomics also announced the culmination of a company recapitalization, including $60 million in financing provided by HealthCare Royalty Partners (HC Royalty), a global healthcare investment firm.

The company has strengthened its management team, appointing Neil J. Campbell president and CEO. Over the past three decades, Campbell has helped commercialize more than 275 life sciences products and services. He has held C-level and senior management positions at Abbott Laboratories, Celera Genomics, Life Technologies (now Invitrogen), EntreMed (now CASI Pharmaceuticals) and SuperNova Diagnostics.

Other senior level appointments include Dane R. Saglio to vice president and chief financial officer, and Ed A. Whigham vice president of sales. Helomics' new board of directors consists of six prominent industry veterans:

  • Todd C. Davis, chairman (HC Royalty, Elan, Abbott)
  • Neil J. Campbell, director (Abbott, Celera Genomics, Life Technologies, EntreMed, SuperNova Diagnostics)
  • Clarke B. Futch, director (HC Royalty, Thomas Weisel Partners, Raymond James)
  • Marc Kozin, director (L.E.K Consulting)
  • D. Stafford O'Kelly, director (Abbott Molecular Diagnostics)
  • Matthew Q. Reber, director (HC Royalty, Oak Hill Capital Partners, Morgan Stanley)

Helomics will offer a more comprehensive set of services to help physicians individualize treatment options for their patients. In addition to the company's core products, ChemoFx, BioSpeciFx and GeneFx, Helomics will offer an expanded platform of Precision Cellular Analytics, genomics and proteomics, as well as bioinformatics and personalized analytics, contract R&D and biorepository and banking.

The company also will be actively looking to acquire new and complementary products to enhance its personalized healthcare platform.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing